Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume – Time to Buy?

Pharvaris N.V. (NASDAQ:PHVS) shares saw unusually-high trading volume on Wednesday . Approximately 99,957 shares traded hands during trading, a decline of 21% from the previous session’s volume of 126,141 shares.The stock last traded at $25.57 and had previously closed at $25.45.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on PHVS shares. Morgan Stanley boosted their price objective on Pharvaris from $34.00 to $37.00 and gave the company an “overweight” rating in a report on Friday, November 14th. Wedbush upped their price objective on Pharvaris from $27.00 to $30.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th. Citigroup reiterated a “market outperform” rating on shares of Pharvaris in a research note on Wednesday, November 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research note on Wednesday, October 8th. Finally, JMP Securities reduced their price target on Pharvaris from $55.00 to $52.00 and set a “market outperform” rating on the stock in a research report on Wednesday, August 13th. Seven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.57.

Pharvaris Price Performance

The company has a market cap of $1.42 billion, a PE ratio of -8.50 and a beta of -2.78. The stock has a 50 day simple moving average of $23.40 and a two-hundred day simple moving average of $21.05.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.08. As a group, equities analysts anticipate that Pharvaris N.V. will post -2.71 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. General Atlantic L.P. increased its stake in Pharvaris by 6.6% during the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after buying an additional 500,000 shares during the period. Foresite Capital Management IV LLC grew its stake in shares of Pharvaris by 8.3% during the third quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock valued at $119,226,000 after acquiring an additional 368,000 shares in the last quarter. venBio Partners LLC grew its stake in shares of Pharvaris by 8.2% during the third quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock valued at $115,751,000 after acquiring an additional 350,000 shares in the last quarter. Deerfield Management Company L.P. increased its position in shares of Pharvaris by 21.1% during the third quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock worth $60,939,000 after acquiring an additional 425,000 shares during the last quarter. Finally, Commodore Capital LP boosted its holdings in Pharvaris by 26.5% in the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock valued at $60,341,000 after purchasing an additional 507,043 shares during the last quarter.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.